Deals Of The Week’s Takeaway From PSA: Optimism With Aches
Executive Summary
The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.
You may also be interested in...
Asia Spotlight: In China, Multinationals Tap Closer R&D Ties With Domestics
As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.
Bonding Time In China: Multinationals Tap Closer R&D Ties With Domestics
As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.
Finding The Value In Shifting R&D Models
Consultancy McKinsey & Co. is optimistic about the future of R&D within the pharma industry, but says certain aspects of the organizations need to shift – making the companies leaner and more productive – to maintain the industry’s leadership position.